VALEO PHARMA INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.08 CAD | -5.88% |
|
-15.79% | -55.56% |
| Apr. 25 | Transcript : Valeo Pharma Inc. - Shareholder/Analyst Call | |
| Mar. 22 | Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors | CI |
| Sales 2024 * | 61M 44.54M | Sales 2025 * | 75.83M 55.37M | Capitalization | 8.39M 6.12M |
|---|---|---|---|---|---|
| Net income 2024 * | -18M -13.14M | Net income 2025 * | -12M -8.76M | EV / Sales 2024 * | 1 x |
| Net Debt 2024 * | 52.53M 38.36M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.11 x |
| P/E ratio 2024 * |
-0.43
x | P/E ratio 2025 * |
-0.65
x | Employees | 100 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.88% |
More Fundamentals
* Assessed data
More news
Latest transcript on Valeo Pharma Inc.
More press releases
| 1 day | -19.05% | ||
| 1 week | -5.56% | ||
| Current month | -10.53% | ||
| 1 month | -10.53% | ||
| 3 months | -56.41% | ||
| 6 months | -45.16% | ||
| Current year | -52.78% |
1 week
0.09
0.11
1 month
0.080.11
Current year
0.060.39
1 year
0.060.41
3 years
0.061.12
5 years
0.001.86
10 years
0.001.86
| Managers | Title | Age | Since |
|---|---|---|---|
Steven Saviuk
FOU | Founder | 65 | 03-03-26 |
Pascal Tougas
DFI | Director of Finance/CFO | - | Nov. 19 |
Nelly Komari
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard MacKay
CHM | Chairman | 89 | 18-07-24 |
Steven Saviuk
FOU | Founder | 65 | 03-03-26 |
Marc Léger
BRD | Director/Board Member | 65 | 22-04-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 0.08 | -5.88% | 24 840 |
| 24-06-06 | 0.085 | -19.05% | 166,500 |
| 24-06-05 | 0.105 | 0.00% | 16,501 |
| 24-06-04 | 0.105 | +5.00% | 10,000 |
| 24-06-03 | 0.1 | +5.26% | 30,000 |
Delayed Quote Toronto S.E., June 06, 2024 at 03:35 pm EDT
More quotes
Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.
Sector
Pharmaceuticals
Calendar
2024-06-12
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.085
CAD
Average target price
0.5
CAD
Spread / Average Target
+488.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -52.78% | 6.13M | |
| +43.64% | 754B | |
| +40.15% | 630B | |
| -6.58% | 352B | |
| +19.72% | 331B | |
| +8.78% | 298B | |
| +11.96% | 217B | |
| -1.19% | 216B | |
| +0.03% | 163B | |
| +6.13% | 164B |
- Stock Market
- Equities
- VPH Stock
